An investigation of clinical outcomes and inflammatory response to heparin free extracorporeal membrane oxygenation support during clinical lung transplantation – a prospective double-blind randomised feasibility study. “Zero-Hep”

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519503-10-00

Acronym

Zero-Hep

Enrollment

Registered

2025-01-30

Start date

2022-12-09

Completion date

Unknown

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung transplantation

Brief summary

arterial or venous thromboembolic events, circuit-related thrombosis

Detailed description

serious bleeding, in-house mortality rate

Interventions

DRUGIsotone Natriumchloridlösung 0

DRUG9 % Braun Injektionslösung

DRUGHeparin Gilvasan 5000 IE/ml – Injektions-/Infusionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
arterial or venous thromboembolic events, circuit-related thrombosis	—

Secondary

Measure	Time frame
serious bleeding, in-house mortality rate	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026